Iteos Therapeutics Inc (ITOS) Stock Price, Quote & News

Company Profile

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cel...

Industry: Biotechnology

Sector: Healthcare

Phone: 339 217 0161

Website: www.iteostherapeutics.com

Address:

321 Arsenal Street, Watertown, United States

AlertsAndNews Aug. 29 at 2:34 AM

$ITOS is t-12 halted here at the AH close.

0 · Reply

TwongStocks Aug. 25 at 9:01 PM

$ITOS NASDAQ Equity Corporate Actions Alert # 2025 - 464 Information Regarding the Tender Offer of iTeos Therapeutics, Inc. (ITOS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-464 The tender offer by Concentra Biosciences, LLC to acquire all of the outstanding common stock of iTeos Therapeutics, Inc. (ITOS) is scheduled to expire one minute after 11:59 p.m. ET on August 28, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on August 29, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 28, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (August 29th) and will be suspended effective September 2, 2025. Tender offer: $10.047, plus one non-transferable contingent value right (CVR) for each share of ITOS held.

0 · Reply

JarvisFlow Aug. 7 at 2:48 PM

Wells Fargo has adjusted their stance on ITeos Therapeutics ( $ITOS ), setting the rating to Equal-Weight with a target price of 12 → 11.

0 · Reply

TheDizPlinTrader Jul. 21 at 12:44 PM

$ITOS 1H Levels Price: $10.28 Support: $9.80 Resistance: $10.95 Lower float mover — coiling again. We now have a free Discord community. Drop a comment if you’d like to join and we’ll send over the invite link.

0 · Reply

TwongStocks Jul. 21 at 12:09 PM

$ITOS Agrees to be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right https://www.globenewswire.com/news-release/2025/07/21/3118625/0/en/iTeos-Therapeutics-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-10-047-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html CVR represents the right to receive: 1) 100% of the closing net cash of ITOS in excess of $475 million. If ITOS has $400M in closing net cash, nothing gets distributed to CVR holders. If ITOS has $500M in net closing cash, then $25M will be distributed to CVR holders 2) 80% of any net proceeds received from any disposition of certain of iTeos’ product candidates that occurs within six months following the closing

0 · Reply

OpenOutcrier Jul. 21 at 11:57 AM

$ITOS (+0.6% pre) Biotech Deal Alert: iTeos Therapeutics Acquired at $10.04 Per Share - Hidden Value in Complex CVR Structure https://ooc.bz/l/70550

0 · Reply

fantasy23 Jul. 21 at 11:30 AM

$ITOS liquidation

0 · Reply

fantasy23 Jul. 21 at 11:27 AM

$ITOS halted

0 · Reply

nico10 Jul. 11 at 4:26 PM

$ITOS is a big move coming? 11 calls for august are really cheap .

0 · Reply

joe77w Jun. 24 at 3:21 PM

$ITOS TANG with 9.99% https://www.otcmarkets.com/filing/html?id=18545810&guid=uNi-kpAMy8JjJth

0 · Reply

ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

Jul 22, 2025, 6:27 PM EDT - 6 weeks ago

ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

Jul 21, 2025, 6:00 PM EDT - 6 weeks ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.

Jul 21, 2025, 7:29 AM EDT - 6 weeks ago

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

May 28, 2025, 8:30 AM EDT - 3 months ago

iTeos Therapeutics Announces Its Intention to Wind Down Operations

May 13, 2025, 7:55 AM EDT - 4 months ago

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Apr 28, 2025, 4:30 PM EDT - 4 months ago

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 25, 2025, 4:35 PM EDT - 5 months ago

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Mar 5, 2025, 7:00 AM EST - 6 months ago

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Feb 27, 2025, 11:00 AM EST - 6 months ago

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

Dec 17, 2024, 7:01 PM EST - 9 months ago

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Dec 12, 2024, 8:55 AM EST - 9 months ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

Nov 26, 2024, 7:00 AM EST - 10 months ago

iTeos to Participate in Upcoming Investor Conferences

Nov 12, 2024, 7:00 AM EST - 10 months ago

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 16, 2024, 8:44 AM EDT - 1 year ago

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

UPST

Sep 15, 2024, 3:37 AM EDT - 1 year ago

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 14, 2024, 2:30 AM EDT - 1 year ago

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Aug 20, 2024, 8:30 AM EDT - 1 year ago

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

Aug 5, 2024, 7:00 AM EDT - 1 year ago

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

Jul 8, 2024, 9:00 PM EDT - 1 year ago

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 8, 2024, 7:00 AM EDT - 1 year ago

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

Jun 17, 2024, 9:00 AM EDT - 1 year ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

May 10, 2024, 9:45 AM EDT - 1 year ago

iTeos Therapeutics to raise $120 million via registered direct offering

May 10, 2024, 8:26 AM EDT - 1 year ago

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:24 AM EDT - 1 year ago

iTeos Therapeutics Announces $120 Million Registered Direct Offering

Apr 7, 2024, 4:30 PM EDT - 1 year ago

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Mar 6, 2024, 7:01 AM EST - 1 year ago

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

Mar 6, 2024, 7:00 AM EST - 1 year ago

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 4:30 PM EST - 1 year ago

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK MRK NVS PFE

Nov 21, 2023, 7:00 AM EST - 1 year ago

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 4, 2023, 9:00 AM EDT - 2 years ago

iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail

Aug 25, 2023, 3:55 PM EDT - 2 years ago

iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall

Aug 23, 2023, 8:45 AM EDT - 2 years ago

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

GILD RCUS

Aug 8, 2023, 7:00 AM EDT - 2 years ago

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 4, 2023, 10:04 AM EDT - 2 years ago

iTeos Therapeutics: Trading Under Cash Value

May 10, 2023, 7:01 AM EDT - 2 years ago

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 15, 2023, 7:00 AM EDT - 2 years ago

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 2, 2023, 2:41 PM EST - 2 years ago

iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through

Feb 28, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at Cowen 43rd Annual Health Care Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at SVB Securities Global Biopharma Conference

Jan 9, 2023, 7:00 AM EST - 2 years ago

iTeos Provides Business Updates and Clinical Development Plans for 2023

Jan 3, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 3 years ago

iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 4:01 PM EST - 3 years ago

iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 10, 2022, 4:01 PM EDT - 3 years ago

iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

Jun 13, 2022, 4:39 AM EDT - 3 years ago

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

AlertsAndNews Aug. 29 at 2:34 AM

$ITOS is t-12 halted here at the AH close.

0 · Reply

TwongStocks Aug. 25 at 9:01 PM

0 · Reply

JarvisFlow Aug. 7 at 2:48 PM

Wells Fargo has adjusted their stance on ITeos Therapeutics ( $ITOS ), setting the rating to Equal-Weight with a target price of 12 → 11.

0 · Reply

TheDizPlinTrader Jul. 21 at 12:44 PM

0 · Reply

TwongStocks Jul. 21 at 12:09 PM

0 · Reply

OpenOutcrier Jul. 21 at 11:57 AM

$ITOS (+0.6% pre) Biotech Deal Alert: iTeos Therapeutics Acquired at $10.04 Per Share - Hidden Value in Complex CVR Structure https://ooc.bz/l/70550

0 · Reply

fantasy23 Jul. 21 at 11:30 AM

$ITOS liquidation

0 · Reply

fantasy23 Jul. 21 at 11:27 AM

$ITOS halted

0 · Reply

nico10 Jul. 11 at 4:26 PM

$ITOS is a big move coming? 11 calls for august are really cheap .

0 · Reply

joe77w Jun. 24 at 3:21 PM

$ITOS TANG with 9.99% https://www.otcmarkets.com/filing/html?id=18545810&guid=uNi-kpAMy8JjJth

0 · Reply

joe77w Jun. 24 at 3:20 PM

$ITOS Concentra in so I would not be surprised with a cash offer plus CVR, just speculation.

1 · Reply

Count__Stockula Jun. 23 at 4:21 AM

$ITOS hear the news last week? Annual shareholder meeting was held. More news coming this week. 😁

0 · Reply

Count__Stockula Jun. 14 at 12:59 PM

$ITOS news coming this week.

0 · Reply

bullwink Jun. 12 at 5:41 PM

$ITOS Is management going to do anything about strategic alterbatives and preserve shareholder capital or just smoke and mirror announcement weeks ago?

0 · Reply

Count__Stockula Jun. 11 at 6:22 AM

$ITOS should be asking whos been buying up shares and why.

0 · Reply

nico10 Jun. 10 at 9:51 AM

$ITOS insiders are selling big...

0 · Reply

nico10 Jun. 9 at 5:51 PM

$ITOS what is the future for this stock? In the last week it didnt moove

0 · Reply

Count__Stockula Jun. 3 at 5:49 PM

$ITOS news soon. Easy buy and wait. Some know and are keeping it to themselves.

0 · Reply

WillisC May. 29 at 7:03 PM

$ITOS Question: this company has $625 million in assets. Where did they get that money? Investors? Loans? Share dilution. They only have 30 million shares. So I don't think they could have raise $ through share dilution. No banks or investors in line for their money? hummmm. How would money just appear....

1 · Reply

TeresaTrades May. 29 at 6:07 PM

Heavy options volume $BIRK $VEEV $ITOS $GRND $EU

0 · Reply

joe77w May. 29 at 4:47 AM

$ITOS 120 mln should be burnt in order to cover Q2/Q3 operating exp plus restructuring costs, legal and adm fees. I dont know how much can be worth asset for sale, current pps fair imo. Too much uncertainty about cash expenditure and distributions. I dont know how much could be worth the compounds for sale.

0 · Reply

EddieH2020 May. 29 at 1:47 AM

$SGMO Could learn a thing from $ITOS PR today

0 · Reply

Market Cap	448.68M
Revenue (ttm)	35.00M
Net Income (ttm)	-134.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-384.03%
Debt to Equity Ratio	0.00

Volume	11,006,800
Avg Vol	1,421,652
Day's Range	N/A - N/A
Shares Out	44.21M
Stochastic %K	42%
Beta	1.49
Analysts	Hold
Price Target	$10.30